Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EPIcyte Pharmaceutical Inc.

This article was originally published in Start Up

Executive Summary

EPIcyte has licensed patents from the Scripps Research Institute covering new methods of human antibody production in plants that can lower costs up to 100 fold. The company is also developing proprietary products based on its technology, initially, an anti-herpes prophylactic and a contraceptive based on an anti-sperm antibody.

You may also be interested in...



Antibodies, Everyone?

A cluster of recent deals indicates just how hot antibodies are right now, and also hints at some old difficulties and new opportunities in the field.

Antibodies, Everyone?

A cluster of recent deals indicates just how hot antibodies are right now, and also hints at some old difficulties and new opportunities in the field.

Women's Health: Too early or Too Late?

As an industry, women's health is in its infancy. It has yet to develop beyond a collection of niche specialties in reproductive medicine and breast cancer.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel